Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) is ending mid-December 2025 in classic clinical-stage biotech fashion: big percentage swings, a sharp momentum breakout, and investors trying to decide whether the move is “new information” or simply “new positioning.” As of Saturday, December 20, 2025, EWTX is being widely quoted around $25.55—a level reached after a powerful jump in the prior U.S. session. StockAnalysis+1 What matters for readers tracking the stock isn’t just the price print. It’s the why: a late-stage neuromuscular story (sevasemten), a closely watched cardiovascular program (EDG-7500), and a pipeline that can re-rate quickly on clinical updates—up or down. PR